Accel-RX Our Partners

Accel-Rx brings together seven of Canada’s leading health sciences Centres of Excellence for Commercialization and Research (CECRs) to foster cross-Canadian co-operation and directly addressing the health science company creation challenge in Canada. They include:

Accel-Rx’s mission is further supported by BDC Capital, a founding partner of Accel-Rx, which provides additional funding for companies created  and/or supported by Accel-Rx. Accel-Rx intends to invest in up to three to four companies annually, with that number potentially increasing as the partnership progresses. Selected companies would receive a $500,000 convertible note from each of Accel-Rx and BDC Capital enabling these companies to attract matching, if not greater investment from the private sector.

A subsidiary of the Business Development Bank of Canada (BDC), BDC Capital offers a full spectrum of specialized financing and investment solutions to help Canadian entrepreneurs achieve their full growth potential. With more than $1.6 billion under management, BDC Capital takes a strategic, patient approach to nurture companies’ development over the long term.  From venture capital and equity, to growth and transition capital, our team of over 100 experienced, local professionals partner with entrepreneurs to identify and meet their needs on flexible terms. Some of the sectors in which we specialize include IT, industrial/clean/energy technology, and healthcare. For more information, please visit or follow us on Twitter at @BDC_Capital.

Canada’s business development bank, BDC, puts entrepreneurs first. With almost 2,000 employees and more than 100 business centres across the country, BDC offers loans,  consulting services, growth and business transition capital, securitization, as well as venture capital to more than 30,000 small and medium-sized companies. Their success is vital to Canada’s economic prosperity.

“Accel-Rx is the kind of highly-strategic & impactful investment to help successfully grow Canada’s biotech sector into a global life sciences leader which will in turn generate significant economic & societal benefits.”

Andrew Casey – President & CEO, BIOTECanada

Subscribe to our mailing list

* indicates required